Drugs / Dual-target CAR-NK cells
Dual-target CAR-NK cells
also known as
EB-DT-CAR-NK (Essen Biotech Dual-Target CAR-NK)
Cell therapy targets CD276, EGFR, ERBB2, MUC1, ROR1 via depletion
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07551336 | Mar 2026 → Apr 2027 expected | glioblastoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1 | NCT07480941 | Feb 2026 → Feb 2027 expected | glioblastoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07510802 | Feb 2026 → Mar 2027 expected | HER2 positive breast carcinoma, triple-negative breast carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07486089 | Feb 2026 → Feb 2027 expected | HER2 positive breast carcinoma, triple-negative breast carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07467863 | Feb 2026 → Feb 2027 expected | non-small cell lung carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-target CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07486089 ↗ |
| Known as | EB-DT-CAR-NK (Essen Biotech Dual-Target CAR-NK) | “EB-DT-CAR-NK (Essen Biotech Dual-Target CAR-NK)” NCT07486089 ↗ |
| Action | Deplete | “NK cells can recognize and kill abnormal cells” NCT07486089 ↗ |
| Modality | Cell therapy | “Allogeneic cord-blood-derived NK cells engineered to express a dual-target CAR” NCT07467863 ↗ |
| Route | Intravenous | “Infused intravenously on Day 0” NCT07467863 ↗ |
| Target | CD276 | “recognize two tumor-associated antigens selected from IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276)” NCT07480941 ↗ |
| Target | EGFR | “recognize two tumor-associated antigens selected from IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276)” NCT07480941 ↗ |